Щ

PTO/SB/21 (09-04)

Under the Paperwork Reduction Act of 1995, no person	U.S. I	Dalams and To	Approved for use through 07/31/2006. Ome des redemark Office; U.S. DEPARTMENT OF COMI primation unless it displays a valid OMB control r	JERCE
Under the Paperwork Reduction Act of 1885, No telec	Application Number	10/035,7		
TRANSMITTAL	Filing Date	Decemb	per 24, 2001 RECE	11/5
FORM	First Named Inventor	Michael	GRAUPE et al. CENTRALE	AYOF
. •	Art Unit	1626		
(to be used for all correspondence after initial filing)	Examiner Name	SHIAO,	Rei Tsang JAN 0	4 200
10	Attorney Docket Number	USAV20	001/0081 US NP	ノ
Total Number of Pages in this Submission				
ENG	CLOSURES (Check al	that apply	/) After Allowance Communication	lo TC
Fee Transmittal Form	Drawing(s)		After Allowance Communication	ا ۵،۵
Fee Attached	Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences	
¬	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
Amendment/Reply	Pelition to Convert to a			
After Final	Provisional Application Power of Attorney, Revocation	DΠ	Proprietary Information	
Affidavits/declaration(s)	Change of Correspondence	Address	Status Letter Other Enclosure(s) (please iden	flfv
Extension of Time Request	Terminal Disclalmer		Other Enclosure(s) (please identification):	
Express Abandonment Request	Request for Refund		1. Form 1449 2. Transmittal of IOS Fee Form	
<del>-</del>	CD, Number of CD(s)		2, transmittal of IDS Fee Form	
Information Disclosure Statement	Landscape Table on C	:0		
Certified Copy of Priority Rem	narks			
Document(s)				
Reply to Missing Parts/				
Reply to Missing Parts	•			
under 37 CFR 1.52 or 1.53				
	OF ADDITIONAL ATT	DNEV (	OR ACENT	
	OF APPLICANT, ATTO	JKNET, C	JR AGENT	
irm Name AVENTIS PHARMACEUTIC	ALS INC.			_
ignature Seed O : Ross	ιĵ			
Printed name (Joseph ROSSI	·			
Date January 04, 2005		Reg. No.	47038	
dentanty on moor				$\overline{}$
CEPTIE	FICATE OF TRANSMIS	SION/MA	II ING	•
hereby certify that this correspondence is being fac				with
sufficient postage as first class mail in an envelope :	addressed to: Commissioner f	or Patents,	P.O. Box 1450, Alexandra, VA 22313-14:	50 on
the date shown below: (USPTO FAX NO. 703-872	2-9306 ; Total No. of P	ages Transi	mitted: 18)	
Signature			<u></u>	
Typed or printed name Paul Irvine			Date January 04, 2005	

This collection of Information is required by 37 CPR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED **CENTRAL FAX CENTER** 

JAN. 4. 2005 2:51PM

AVENTIS US PAT DEPT

JAN 0 4 2005

NO. 1077 P. 2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of GRAUPE, et al.

Examiner:

Robert Shaio

Art Unit:

1626

Application No.: 10/035,783

Filed: 12/24/2001

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile to

the Commissioner for Patents, Alexandria, VA 22313, on

January 4, 2005

Date of Transmission

Signature

Compositions As Cathespin Inhibitors

Title: Novel Compounds and

## INFORMATION DISCLOSURE STATEMENT <u>UNDER 37 C.F.R. 1.56, 1.97 AND 1.98</u>

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

 $\Box$ 

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

$\boxtimes$	(b)	This	Information Disclosure Statement is filed after the period set forth in 37 C.F.R.
		1.97	(b), but is believed to be filed before the mailing date of a final action under §1.113
		or a	notice of allowance under §1.311, whichever occurs first.
		<b>(1)</b>	The undersigned attorney certifies that each item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application not more than three months prior
	•		to the filing of this statement;
		(2)	The undersigned attorney certifies that no item of information contained in this
			Information Disclosure Statement was cited in a communication from a foreign
			patent office in a counterpart foreign application or, to the knowledge of the
			undersigned attorney after making reasonable inquiry, was known to any
			individual designated in §1.56(c) more than three months prior to the filing of this
			statement; or
	$\boxtimes$	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is
			authorized.

A concise explanation of the relevance of some or all of the items listed on the attached PTO-1449 (modified) is as follows:

The items listed on pages 1-13 of the attached PTO-1449 have been previously submitted to the Patent Office or cited by the Examiners during the prosecution of the following patents or patent applications commonly owned by the assignees of record of the present case: U.S. Patent Nos. 6,576,630, 6,506,733, 6,455,502 and 6,492,362; and U.S. Patent Application Nos. 10/183,128, 10/294,526, 10/719,080, 10/787,367, 10/418,183 and U\$02/17922 (PCT application filed in the U.S. receiving office).

Therefore, a copy of the reference is not enclosed with this Information Disclosure Statement. However, the applicant will furnish a copy of any listed reference, if so requested by the Examiner.

Respectfully submitted,

Joseph D. Rossi, Reg. No. 47,038 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626

Aventis Docket No. USAV2001/0081 US NP

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner: Robert Shaio

GRAUPE, et al.

Art Unit:

1626

Application No.: 10/035,783

Filed: 12/24/2001

Title: Novel Compounds and

Compositions As Cathespin

**Inhibitors** 

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, Alexandria, VA 22313, on

January 4, 2005

Date of Transmission

Signature

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

mey/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-3410 Telefax (908) 231-2626

Aventis Docket No. USAV2001/0081 US NP

Please type a plus sign (+) inside this box 👄	۱,	7
	_	_

PTO/SE/08A (10-96)
Approved for use through 10/31/99, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO Application Number 10/035,783 INFORMATION DISCLOSURE Filing Date 12/24/2001 STATEMENT BY APPLICANT First Named Inventor GRAUPE **Group Art Unit** 1626 (use as many sheets as necessary) Examiner Name Shaio Sheet of 13 Attorney Docket Number USAV2001/0081 - US - NP

				U.S. PATENT DOCI	JMENTS	
Examiner Inilials	Cite Na.1	U,S, Paten Number	t Document Kind Gode <sup>2</sup> (# known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columna, Lines, Where Relevant Passages or Relevant Figures Appear
		4,927,609		STUBER, et al.	05-22-1990	rida de Milder
		5,424,325		ANDO, et al.	06-13-1995	
		5,486,623		ZIMMERMAN, et al.	01-23-1996	
		5,498,616		MALLANO, et al .	03-12-1996	
		5,847,135		BEMIS, et al.	12-08-1998	<del></del>
		5,852,007		CHATTERJEE, et al.	12-22-1998	
		5,874,424		BATCHELOR, et al.	02-23-1999	
		5,998,390		RAMAMURTHY, et al.	12-07-1999	
		6,004,933		SPRUCE, et al.	12-21-1999	<del></del>
		6,022,861		SCARBOROUGH, et al.	02-08-2000	
		6,114,310		CHAMBERLAND, et al.	09-05-2000	
		6,124,333		MILLER, et al.	12-26-2000	
		6,255,453		GYORKOS	07-03-2001	
		6,353,017		ALTMAN, et al.	03-05-2002	
		6,455,502		BRYANT, et al.	09-24-2002	
		6,476,026		BRYANT, et al.	11-05-2002	
		6,492,362		GRAUPE, et al.	12-10-2002	
		6,506,733		BUYSSE	01-14-2003	•
		6,576,630		LINK, et al.	06-10-2003	
		<u> </u>			1	

				FOR	EIGN PATENT DOCUMENT	វន		
Examiner			Foreign Patent Do	cument Kind Code <sup>s</sup>	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	Ī
Initials*	No.1	Office	Number <sup>4</sup>	(if known)	Applicant of Cited Document	MM-DD-YYYY	Passages of Relevant Figures Appear	Tβ
		EP	EP 0272671		KRANTZ, et al.	06-29-1988		$\prod$
		EP	EP 0291234		EDWARDS, et al.	11-17-1998		$\Box$
		EP	EP 0355572		PAQUES, et al.	02-28-1990		
		EP	EP 0376012		ALBRIGHT, et al.	07-04-1990		
		EP	EP 0419683		HARA, et al.	04-03-1991		
		EP	EP 0536399		OKUBO, et al.	04-01-1993		
		EP	EP 0652009		DOVEY, et al.	10-05-1995		
		EP	EP 0754454		KOBAYASHI, et al.	01-22-1997		
		JP	JP 06192199		RYOICHI, et al.	07-12-1994		
	·	JP	JP 42009133		IRIKURA, et al.	05-06-1967		

Examiner	Dat	te	
Signature	Cor	nsidered	

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		sign (+) inside this wrk Reduction Act	Ľ	persons are required to m	Patent and Iradem	PTO/SB/08A (10-96) proved for use through 10/31/99. OMB 0651-0031 sark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.	+
1		ule for form 1449A				omplete if Known	1
	15.15	ODMATIC	NI DIO	01.001155	Application Number	10/035,783	†
				CLOSURE	Filing Date	12/24/2001	†
	STA	ATEMENT	BY AF	PPLICANT	First Named Inventor	GRAUPE	1
		<b></b> .			Group Art Unit	1626	1
. !		(изе ав талу	sheets as n	ecessary)	Examiner Name	Shaio	1
•	Sheet	2	of	13	Attorney Docket Number	USAV2001/0081 - US - NP	J

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	U.S. Patent	Cocument Kind Codes (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Rolevant Figures Appear			
		10/035,783		GRAUPE, et al.	12-24-2001				
		10/719,080		GRAUPE, et al.	11-21-2003				
		U\$02/17922		GRAUPE, et al.	11-24-2003	<del></del>			
		10/787,967		GRAUPE, et al.	9-16-2002				
		10/418,183		LI, et al.	10-23-2003				
			[						
		:							
			-						
				•	<u> </u>				
<del></del> _					<u> </u>				
	J		1 1						

			·	FOR	EIGN PATENT DOCUMENT	rs		
Examiner Initials'	Cite No.1	Office	Foreign Patent Do	Cument Kind Code <sup>5</sup> (# known)	Name of Palentee or Applicant of Cited Document	Date of Publication of Cited Decument MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear	T <sup>6</sup>
		JP	JP 63303868		YOSHIDA, et al.	12-08-1988		
1 1		wo	WO 00/48992		TUCKER, et al.	08-24-2000		$\top$
		wö	WO 00/49007		TUCKER, et al.	08-24-2000	^ *	1
		WO	WO 00/49008		TUCKER, et al.	09-24-2000	·	$\top$
		wo	WO 00/51998		CYWIN, et al.	09-08-2000		1
		wo	WO 00/59881		SINGH, et al.	10-12-2000	· · · · · · · · · · · · · · · · · · ·	1
		wo	WO 00/69855		QUIBELL, et al.	11-23-2000		$\top$
		WO	WO 01/09110		BEKKALI, et al.	02-08-2001		$\top$
	, and the second	wo	WO 01/19796		GRAUPE, et al.	03-22-2001		$\top$
		wo	WO 01/19808		GRAUPE	03-22-2001		

Examiner	 Date	
Signature	Considered	
		L

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard \$T.3). <sup>4</sup> For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language Translation is attached.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not obtain is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		sign (+) inside this i rark Reduction Act o		ensons are required to n	Aor Petent and Traderr Spond to a collection of Informati	PTO/SB/08A (10-96) Droved for use through 10/31/89, OMS 0651-0831 DEPARTMENT OF COMMERCE ON UDIESS it contains a valid OMS control number.	_
ſ	·	ite for form 1449A/F				complete if Known	Ì
ı	INTE	ODRAKTIO	N DIGG	. COURT	Application Number	10/035,783	ľ
1		ORMATIO			Filing Dato	12/24/2001	Ì
	STA	TEMENT	<b>BY AP</b>	PLICANT	First Named Inventor	GRAUPE	İ
		<b>6.4.</b>			Group Art Unit	1626	
L		(use as many si	heets as ne	cessary)	Examiner Name	Shaio	ĺ
(	Sheet	3	of	13	Attomey Docket Number	USAV2001/0081 - US - NP	ſ

				U.S. PATENT DOC	UMENTS	
Examiner	Cite	U.S. Paler	t Document	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant
Initials*	No.¹	Number	(if known)	of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
				· · · · · · · · · · · · · · · · · · ·		•
[						
						<del></del>
						· · · · · · · · · · · · · · · · · · ·
				<b></b>		"
			<u> </u>			
				•		<i>M</i>
						· - ·

				FOR	EIGN PATENT DOCUMEN	TS		
Examiner Initiala'	Cile No.1	Office	Foreign Patent Do	Curnent Kind Code <sup>5</sup> (# known)	Name of Patentes or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Linus, Where Relevant Passages or Relevant Figures Appear	Te
		wo	WO 01/19816		EMMANUEL, et al.	03-22-2001		$\Box$
		W O	WO 01/30772		TUCKER, et al.	05-03-2001		$\Box$
		wo	WO 01/55125		BOZSING, et al.	08-02-2001		1
		wo	WO 01/58886		MISSBACH, M	08-16-2001		$\top$
		wo	WO 95/13069		MORRIELLO, et al.	05-18-1995		$\Box$
		wo	WO 95/15809		JENKINS, et al.	06-08-1995		$\top$
		wo	WO 95/24382		HALLINAN, et al.	09-14-1995		$\Box$
		WO	WO 96/21655		PEET, et al.	07-18-1998		$\Box$
		wo	WO 96/30353		PALMER, et al	10-03-1996		1
		WO	WO 96/40647		ZIMMERMAN, et al.	12-19-1996		$\Box$

Examiner	Date	
Signature	Considered	

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		sign (+) inside this bo rork Reduction Act of 1			App Patent and Tradem spond to a collection of informatic	PTO/SB/08A (10-96) arved for use through 10/31/98. OMB 0551-0031 ark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.
- (	Subsili	ule for form 1449A/PT(	כ		C	omplete if Known
1	INFORMATION DISCLOSURE		DOL COURT	Application Number	10/035,783	
- 1					Filing Date	12/24/2001
	STA	ATEMENT B	Y A	APPLICANT	First Named Inventor	GRAUPE
				_	Group Art Unit	1626
L		(use as many she	ėlė e	necessary)	Examiner Name	Shaio
	Sheet	4	of	13	Altomey Docket Number	USAV2001/0081 - US - NP

			U.S. PATENT DOC	JMENTS	
Cite No.1	U.S. Paten Number	Kind Code <sup>2</sup> (# known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pagos, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
					<u> </u>
			<del></del>		
			· · · · · · · · · · · · · · · · · · ·		<u> </u>
			·· ·		
	·				
		<del></del>			<del></del>
		<del></del>			
					<del></del>
		$\longrightarrow$			
		<del> - -</del>		<del> </del>	
		Cite No.1 Number	No.1 Number Kind Code <sup>2</sup> (# known)	Cite No.1 Number Kind Code (# Innown)  Name of Patentee or Applicant of Cited Document  Name of Patentee or Applicant of Cited Document	Cite No.1 Number Kind Code <sup>2</sup> (# known)  Name of Patentee or Applicant Cited Document MM-DD-YYYY  Of Cited Document MM-DD-YYYY

·			-	FOR	EIGN PATENT DOCUMENT	rs		
Examiner	Cite		Foreign Patent Do		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant	Т
Iniliala*	No,1	Office	Number*	Kind Code <sup>8</sup> (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Τŝ
		wo	WO 96/40744		MARLOWE, et al.	12-19-1996		T
		wo	WO 96/41638		DOLLE, et al.	12-27-1998		
		wo	WO 97/03679		MALLANO, et al.	02-06-1997		
		WO	WO 98/01133		AIBE, et al.	01-15-1998		
		WQ	WO 98/01428		DOMINGUEZ, et al.	01-15-1998		
		wo	WO 98/05336		MARQUIS, et al.	02-12-1998		1
		wo	WO 98/08802		YAMASHITA, et al.	03-05-1998		$\top$
		wo	WO 98/08867		SHIONOGI, et al.	03-05-1998		$\top$
		8	WO 98/21188		PRESTON, et al.	05-22-1998		$\Box$
		WO	WO 98/23588		FLOYD, C.	06-04-1998		$\Box$

Examiner	•	Date	•
Signature		Considered	
		 ***************************************	<u></u>

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sertal number of the petent document. <sup>3</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



<sup>\*</sup>EXAMINER: Initial if reference considered, whicher or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Substitute for form 1449A/PTO  INFORMATION DISCLOSURE			o persons are required to r	App Palent and Tradom espond to a collection of informatic	PTC/SE/08A (10-96)  roved for use through 10/31/99, OMB 0851-0031  ark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid CMB control number,
- (	Substit	Jie for form 1449A/	PTO		c	omplete If Known
	INIT:	ODMATIO		or cours	Application Number	10/035,783
			Filing Date	12/24/2001		
	STA	<b>ATEMENT</b>	BY A	PPLICANT	First Named Inventor	GRAUPE
		<b></b> .			Group Art Unit	1626
L		(USO BS MBNY S	heets as	necessary)	Examiner Name	Shaio
	Sheet	5	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

				U.S. PATENT DOCU	JMENTS	-	
Examiner	Cite	U.S. Patcht Document		Name of Patentce or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant	
initials"	No.1	Number	Kind Godo <sup>2</sup> (II known)	of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	
	1						
	]					<del></del>	
			[ ]				
				•	· · · · · · · · · · · · · · · · · · ·		
				· · ·			
	$\neg$				<del>-</del>	***************************************	
						•	
					<del>- </del>	***	
		· · · · · · · · · · · · · · · · · · ·			<del>                                     </del>		
		-			<del>                                     </del>		
<del>-  </del>					<del> </del>		
$\overline{}$	一十				<del> </del>		
			<del>- } -  </del>		+		
<del></del>			<del>      -</del>				

				FOR	EIGN PATENT DOCUMEN	rs		
Examiner Inilials*	Cite No.1	Office	Foreign Palent Do	Cument Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Tå.
		WQ	WO 98/49190		SPRUCE, et al.	11-05-1998		
		wo	WO 99/24460		ALTMANN, et al.	05-20-1999		
						<del>                                     </del>		$\vdash$
						<del> </del>		+
			<u> </u>		·			Н

Examiner	Date
Signature	Considered
- Organization	Considered

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	us sign (+) Inside th work Reduction Ac			Pittent and Tredesi	pro/SB/08B (10-96) proved for use through 10/33/28. OMB 0663-0031 park Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.
<i>(</i>	te for form 1449B/I				omplete if Known
				Application Number	10/035,783
INFO	JRMATIC	ט אנ	ISCLOSURE	Filing Date	12/24/2001
I STA	TEMENT	BY	APPLICANT	First Named Inventor	GRAUPE
1				Group Art Unit	1626
	(use as man	y sheet:	as necessary)	Examiner Name	Shaio
Sheet	6	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the							
Examiner Initials*	No.1 item (book, magazine, journal, serial, symposium, cetalog, etc.), date, page(s), volume-issuo number(s publisher, city and/or country where published.								
		ADAMS, et al., Potent and Selective Inhibitors of the Proteasom: Dipeptidyl Boronic Acids, Biooganic & Medicinal Chemistry Letters, 8: 333-338 (1998).							
		ASHWORTH, et al., 4-Cyanothiazolidides as very potent, etable inhibitors of dipeptidyl peptidase (V, Bioorganic & Med. Chem. Letters, B,Oxford, 6(22):2745-2748 (1996).							
		BERGEMAN, et al., Studies on the reactivity of alphacyano.alpha-lsocyano alkanoates. Versitile synthons for the assembly of imidazolea, Helv.Chim. ACTA, 82(6):909-918 (1999).							
		BILLSON, et al., The Design and Synthesis of Inhibitors of the Cystelnyl , Bloorg. Med. Chem. Lett. vol. 8, pp. 983-998, 1998	_						
		BROMME, et al., Potent Inactivation of Cathepsins S and L , Biol. Chem. Hoppe-Seyler. vol. 375, No. 5, pp. 343-347, 1994.							
		CHATTERJEE, et al., D-Amino Acid Containing, High-Affinity Inhibitors of Recombinant Human Calpain I, Journal of Medicinal Chemistry, vol. 41, No. 15, p. 2663-2666 (1998).							
		COHEN, et al., Therapy of relapsing multiple scierosis. Treatment approaches for nonresponders, Journal of Neuroimmunology, 98: 29-36 (1999).							
		DUFOUR, et al., Engineering nitrile hydratase activity into a cysteine protease by a single mutation, Bio.chemistry, US, Am. Chem. Soc., Easton, PA, 34(50):16382-16388 (1995).							
		EDWARDS, et al., Design, Synthesis, and Kinetic Evaluation of a Unique Class of Elastase Inhibitors, the Peptidyl a-Ketobenzoxazoles, and the X-ray Crystal Structure of the Covalent Complex between Porcine Pancreatic Elastase and Ac-Ala-Pro-Val-2-Benzoxazole, Journal of American Chemical Society, vol. 114, No. 5, p 1854-1863 (1992).							
	ļ	EVOLI, et al., abstract only, Drugs, 1996, 52(5), 662-70							
l	ļ								

	-	
Examiner	Date	
Signature	Considered	
444		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English tanguage Translation is attached.

Please type a plus sign (*) Inside this box -> PTC/SB/08B (10-86) Approved for use through 10/31/99, OMB 0681-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.								
Substitu	ite for form 1449B/F	TO		Co	omplete if Known			
	00544716			Application Number	10/035,783			
INF	JRIMATIC	ט אנ	ISCLOSURE	Filing Date	12/24/2001			
STA	TEMENT	BY	APPLICANT	First Named Inventor	GRAUPE			
			,,	Group Art Unit	1626			
	(use as man	<u>y sheet</u>	s as necessary)	Examiner Name	Shaio			
Sheet	7	of	13	Altorney Docket Number	USAV2001/0081 - US - NP			

	_	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	,
Examiner City Initials* No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, aymposium, catalog, etc.), date, page(s), volume-issue number(a), publisher, city and/or country where published.	T <sup>2</sup>
		GOUR-SALIN, et al., Inhibition of papain by peptide nitriles: conversion of the nitrile group into other functionalities via the papain:nitrile thiomidate ester adduct, Can. J. of Chem, CA, National Research Council. Ottawa, 69(8):1288-1297 (1991).	
•		HALLEGUA, et al., Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature, Lupus, 9: 241-251 (2000).	
		HANZLIK, et al., Reversible covalent binding of peptide nitriles to papain, Biochim. Biophys, Acta, vol. 1035, No. 1, 1990, pp. 62-70.	
		HARRIS, et al., Characteristics of a continuous fluorogenic assay for calpain I. Kinetic evaluation of peptide aldehydes, halomethyl ketones and )achalasia) methyl ketones as inhibitors of the enzyme. Chemical Abstracts, 110:7, Bioorg. Med. Chem. Lett. 5(4) 393-398 (1995).	
		HEITMILLER, R.F., abstract only., Semin. Thorac. Cardiovasc. Surg., 1999, 11(1), 41-6	
		KATRITZKY, et al., Benzotriazole-assisted synthesis of alpha(acylamino) nitrites and a conceptually novel method for peptide elongation, Chem. Soc., Perkin Trans. 1(7):1853-1857 (1990).	
		KHAMASHTA, et al., Expert. Opin. Investig. Drugs, 2000, 9(7), 1581-93.	
		KRANTZ, et al., Peptidyl (Acyloxy)methyl Ketones and the Quiescent , Biochemistry. vol. 30, pp. 4878-4687, 1991	
		LEVY, E.G., Baillieres Clin. Endocrinol. Metab., 1997, 11(3) 585-595	
		LI, et al., Aminoacylpyrrolidine-2-nitriles: Potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26), Archivee of Biochem. and Bioph., 323(1)148-154 (1995).	

Examiner	Date	
Signature	Considered	
`		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Pro/SB/08B (10-98) Approved for use through 10/31/89. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Inder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.								
Substitu	ite for form 1449B/PT	o.		С	omplete if Known			
l we			1001 001107	Application Number	10/035,783			
			ISCLOSURE	Filing Date	12/24/2001			
STA	TEMENT	BY	APPLICANT	First Named Inventor	GRAUPE			
ŀ				Group Art Unit	1626			
ļ	(use as many	sheet	s as necessary)	Examiner Name	Shaio			
Sheet	8	of	13	Altorney Dockel Number	USAV2001/0081 - US - NP			

 7	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the frem (book, magazine, journal, señal, symposium, catalog, etc.). date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	LIPSHUTZ, et al., Chiral induction in orginally racemic amino acids via 5-acyl and 5-acyloxyaminooxazoles, lsr, J. Chem. 27(1):49-55 (1986), abstract.	
	LIPSHUTZ, et al., Heterocycles as masked diamide/dipeptide equivalents. Formation and reactions of substituted 5-(acytamino)oxazoles as intermediates en route to the cyclopeptide alkaloids, . Am. Chem. Soc., 105(28):7703-7713 (1983).	
	LIPSHUTZ, et al., Oxazolophanes as masked cyclopeptide alkaloid equivalents: cyclic peptide chemistry without peptide couplings, J. Am. Chem. Soc., 112(19):7032-7041 (1990).	
	MARQUIS, et al., Potent dipeptidylketone inhibitors of the cysteine protease cathepsin, Chemical Abstracts, 7:4 581-588 (1999).	
	MCMATH, et al., Direct dialkylation of peptide nitriles. Application of the synthesis of 1-aminocyclopropane-1 carboxylic acid (Acc)-containing dipeptides, Bull. Soc. Chim. Fr. 134(1):105-110 (1997).	
	MORIYA, et al., Synthesis and Hypolipidemic Activities of 5-Thienyl-4-oxazoleacetic Acid Derivatives.sup.1, J. Med. Chem., 29: 333-341 (1986).	
- 1	MOSER, et al., 130 Poly (dipeptamidinium)-Salze: definition und metoden zur praparativen herstellung, poly (dipeptamidinium) salts: definition and methods of preperation, Helvitica Chimica ACTA, CH, Verlag, Basel 69:1224-1262 (1986).	
	NIPPON, K., Patent Abstracts of Japan, Publication No. 62301868, 013(137)(1988), abstract.	
	NORTH, et al., Synthetic studies towards cyclic peptides. Concise synthesis of thiazoline and thiazole containing amino acids, Tetrahedron, 46(24):8627-8290 (1990).	
0	OGILVIE, et al., Peptidomimetic inhibitors of the human cytomegalovirus protease, Journal of Medicinal Chemistry vol. 40 No. 25 (1997).	

Examiner	1	Date	
	· '	Dale	1
Signature	′	Considered	1
		, 00:10:11:10	

<sup>&#</sup>x27;EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

	us sign (+) inside th work Reduction Ac		· -	Datast and Trades	PTC/SB/08B (10-98) proved for use through 10/31/99. OMB 0851-0031 lark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.
<i>[</i>	le for form 1449B/F				omplete if Known
INFORMATION DISCLOSURE				Application Number	10/035,763
i i				Fillng Date	12/24/2001
STA	TEMENT	BY	APPLICANT	First Named Inventor	GRAUPE
1				Group Art Unit	1626
	(use as man	y sheet	g as necessary)	Examiner Name	Shaio
Sheet	9	of	13	Attorney Dockel Number	USAV2001/0081 - US - NP

	Ĭ	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETYERS), title of the article (when appropriate), title of the	Τ-
Examiner nilieis*	Cite No.1	item (book, magazine, journal, senial, symposium, catalog, etc.), date, page(s), volume-issue number(s).  publisher, city and/or country where published.	1
		PICKEN, et al., inhibition of bovine cathepsin B by amino acid-derived nitriles, Biochemical Society Transactions, vol. 18, No. 2, p:316 (1990).	
		PLIURA, et al., Comparative behavior of colpain and cathepsin B , Biochem. J. vol. 288, pp. 759-762, 1992	
		POLMAN, et al., Drug treatment of multiple sclerosis , BMJ, 321: 19-26 (2000).	
_		RIESE, et al., Essential Role for Cathesin S in MHC Class II-Associated Invariant Chain Processing and Peptide Loading, Immunity, 4: 957-366 (Apr. 1996).	
·		SMITH, et al., New Inhibitors of Cysteine Proteinases, J. Am. Chem. Soc. vol. 110, No. 13, pp. 4429-4431, 1988	-
		SUAVE, et al., Carboxylmodified amino acids and peptides, I An efficient method for the synthesis of monofuctionalized enamines and monofuntionalized methyl ketone derivatives form thioamides via episulfides and thiominium salts, Tetrahedron Lett, 29:19 2295-2298 (1988).	
		SUZUE, S., Hepatic agents. I. Synthesis of aminocyl (and hydroxyacyl) aminoacetoritriles, Chem. and Pharm. Bull. (Tokyo) (1968), 16(8), 1417-32.	
		SUZUE, et al., Studies on Haptic Agents, Chem. Pharm. Bull. vol. 16, No. 8, pp. 1417-1432, Aug. 1968.	
		SUZUKI, et al., Synthesis of 2-Aryl-4(3-thienyl)imidazole Derivatives with Antinflammatory Properties .sup.1), Chem. Pharm. Bull, 34(8); 3111-3120 (1998).	•
		TAO, et al., Inhibition of Calpain By Peptidyl Heterocycles, Bloorganic & Medicinal Chemnistry Letters, 6:24 3009-3112 (1996).	

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

<u></u>	App Patent and Tradem spand to a collection of informatk	PTC/SB/08B (10-98) arcwed for use through 10/31/99. OMB 0891-0031 ark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.
	1	omplete if Known
1001 0011	Application Number	10/035,783
	Filing Date	12/24/2001
APPLICANT	First Named Inventor	GRAUPE
	Group Art Unit	1626
as necessary)	Examiner Name	Shaio
13	Allomey Docket Number	USAV2001/0081 - US - NP
)	ISCLOSURE APPLICANT S as necessary)	Patent and Tradem Co Application Number Filling Date First Named Inventor Group Art Unit Examiner Name

	_	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite Na,1								
		THOMPSON, et al., Carboxyl-modified amino acids and peptides as protease inhibitors, J. Med. Chem., 29(1):104-111 (1986).							
	TSUTSUMI, et al., Synthesis and Structure-Activity Relationships of Peptidyl a-Keto Heterocycles as Novel Inhibitors of Protyl Endopeptidase, Journal of Medicinal Chemistry, vol. 37, No. 21, p 3492-3502 (1994).								
	VARGHA, E., Peptide derivatives. VI. N-protected di- and tripeptide nitrites, Stud. Univ. Babes-Bolyal, Ser. Chem., 19(2):31-5 (English abstract of article in Romanian) (1968).								
_		VARGHESE, The structure and resonance Raman spectrastructure correlations for methyloxycarbonyl-L-phenylalanyl-L-alanine ethyl dithloester, Can. J. Chem., 64(8):1868-1873 (1986).							
	YAMADA, et al., Studies of unusual amino acids and their paptides. IX. The synthetic study of bottomycine and B2, Bul. Chem. Soc., Jpn. 51(3):878-83 (1978), abstract.								
		, Derwent Abstract of Japanese Patent Application 06-192199 , (Jul. 12, 1994).							
ļ									
	_								
Examiner Signature		Date Considered							

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique dilation designation number. 2 Applicant is to place a check mark here If English language Translation is attached.

	sign (+) inside this i	<u> </u>	en at beniupen ens sname		PTC/SB/08A (10-96)
- 7	ute for form 1449A/P			i .	omplete if Known
INE	INFORMATION DISCLOSURE			Application Number	10/035,783
	INFORMATION DISCLOSURE			Filing Date	12/24/2001
STA	ATEMENT	BY AP	PLICANT	First Named Inventor	GRAUPE
1	INFORMATION DISCLOSUR STATEMENT BY APPLICAN (use as many sheets as necessary)			Group Art Unit	1626
	(use as many si	neers as ne	cessary)	Examiner Name	Shaio
Sheet	11	of	13	Attorney Docket Number	USAV2001/0081 - US - NP

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	V.S. Patent Number	Kind Code <sup>2</sup>	Name of Palentee or Applicant of Cited Document	Data of Publication of Cited Document MM-DD-YYYY	Pagas, Columns, Lines. Where Rolovant Passages of Relevant	
		09/927,188		CAI, et al.	08-10-2001	Figures Appear	
		09/927,324		BUTLER, et al.	08-10-2001		
		09/928,122	_	BREITENBUCHER, et al.	08-10-2001	<del>-</del>	
_		09/946,214		GU, et al.	09-05-2001		
		10/042,565		QUIBELL, et al.	11-16-2001	•	
		10/148,612		OHMOTO, et al.	08-21-2002	<del>.</del>	
		10/148,613		OHMOTO, et al.	08-28-2002		
		10/181,713		OHMOTO, et al.	07-22-2002		
		10/161,799		OHMOTO, et al.	07-23-2002		
		10/231,425		BUXTON, et al	08-28-2002		
		10/256,512		BEKKALI, et al.	09-27-2002		
		10/258,053		CUMMINGS, et al.	10-17-2002	· · · · · · · · · · · · · · · · · · ·	
		10/275,583		COWEN, et al.	11-07-2002		
		10/279,424		BEKKALI, et al.	10-24-2002		
		10/466,385		QUIBELL, et al.	01-08-2004		
	_	6,015,791	[[	GYORKOS, et al.	01-18-2000		
		6,608,057		CYWIN, et al.	08-18-2003		
-	_	<del></del>	++		<del>                                     </del>		
		• •			<del> </del>		

				FOR	EIGN PATENT DOCUMEN	ΤŚ		
Examiner Cits	Cita		Foreign Patent Doci	ıment	Name of Patentee or	Date of Publication of	Pages, Columne, Lines,	T
initials.	No.1	Office	Number <sup>4</sup> (if known)		Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	Te
		JP	JP 2001-011037		SATO, et al.	01-18-2001	_	Т
		JP .	JP 2001-055366		SATO, et al.	02-27-2001	******	Ì
		wo	WO00/59881		SINGH, et al.	10-12-2000		1
		WO	WO01/09169		SINGH, et al.	02-08-2001		T
		wo	WO02/057248		QUIBELL, et al.	07-25-2002		1
		WO	WO02/057249		QUIBELL, M	07-25-2002		1-
		WO	WO02/057270		QUIBELL, M	07-25-2002		1
		wo	WO02/096892		OHMOTO, et al.	05-30-2002		$\vdash$
		wo	WO02/100849		HICKEY, et al.	12-19-2002		†
		WO	WO02/20485		BEKKALI, et al.	03-14-2002	·	<del> </del>

Examiner	Date
Signature	Considered
	- Contracted

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents, <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.



<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	lus sign (+) inside tl rwark Reduction Ac			PTO/SB/08B (10-96) Approved for use through 10/31/99. OMB 0681-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Espond to a collection of information unless it contains a veild OMB control number.			
Substitu	ute for form 1449B/i	РΤΟ		C	omplete if Known		
INFORMATION DIGGLOOUSE		Application Number	10/035,783				
	INFORMATION DISCLOSURE		Filing Date	12/24/2001			
STA	TEMENT	BY	APPLICANT	First Named Inventor	GRAUPE		
				Group Art Unit	1626		
	(use as man	y sheets	as necessary)	Examiner Name	Shalo		
Sheet	12	of	13	Attorney Docket Number	USAV2001/0081 - US - NP		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	_
	Cite No,1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-lasse number(s), publisher, city and/or country where published.	7
j		CHAPMAN, et al., Emerging Roles for Cysteine Proteases In Human Biology, Ann. Rev. Physiol.; 1997; 59; pp.63-88.	
		DRANOFF, et al., Cathepsin S Required for Normal MHC Class II Peptide Loading and Germinal Center Development, Immunity; 1999; 10; pp.197-208.	
		FENWICK, et al., Diastereoselective Synthesis, Activity and Chiral Stability of Cyclic Alkoxyketone Inhibitors of Cathepsin K., Bioorg. Med. Chemm. Lett.; 2001; 11(2); pp.199-202.	-
		FENWICK, et al., Solid-phase Synthesis of Cyclic Alkoxyketones, Inhibitors of the Cysteine Protease Cathepsin K., Bioorg. Med. Chem. Lett.; 2001; 11(2); pp.195-198.	
		GREENSPAN, et al., Identification of Dipeptidyl Nitrlles as Potent and Selective Inhibitors of cathepsin B Through Structure-based Drug Design, J. Med. Cham.; 2001; 44; pp.4524-4534.	   
		LOWE, et al., Kinetio Specificity in Papain-catalyzed Hydrolyses, Biochem. J.; 1971; 124(1); pp.107-115.	
		MACIEWICZ, et al., A comparison of Four Cathepsins (B,L,N and S) with Collagenolytic Activity From Rabbit Spleen, Biochem J.; 1998; 256; pp.433-440.	
		MARQUIS, et al., Azeanone-based Inhibitors of Human and Rat Cathepsin K., J. Med. Chem.; 2000; 44(9); op.1380-1395.	
		NAKAGAWA, et al., Imparied invariant Chain Degradation and Antigen Presentation and Diminished Collagen-Induced Arthritis in Cathepsin S-null Mice, Immunity; 1999; 10; pp.207-217.	
	7	OTTO, et al., Cysteine Proteases and their inhibitors, Chem. Rav.; 1997; 97; pp.133-171.	
ł			

Examiner		Data	_
		Date	
Signature		Considered	1
<u> </u>	 	Cousideren	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not chatton is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

	ius sign (+) in <del>sid</del> e th			App Palent and Tradem	PTO/SB/088 (10-96) roved for use through 10/31/99. OMB 0651-0031 ark Office: U.S. DEPARTMENT OF COMMERCE	+
Under the Paper	work Reduction Act	of 1996	no persons are required to re-	spond to a collection of information	on unless it contains a valid OMB control number.	
Substite	ite for form 1449B/F	то		Co	omplete if Known	
l				Application Number	proved for use through 10/31/99. OMB 0651-0031 merk Office: U.S. DEPARTMENT OF COMMERCE tion unless it contains a valid OMB control number.  Complete if Known  10/035,783  12/24/2001  GRAUPE  1626  Shaio	
INF	DRMATIC	)N C	ISCLOSURE	Filing Date	12/24/2001	
STA	TEMENT	BY	APPLICANT	First Named Inventor	GRAUPE	
"			AL I LIQALLI	Group Art Unit	1626	
<u></u>	(use as many	y sheet	s as necessary)	Examiner Name	Shaio	
Sheet	13	of	13	Atlomey Docket Number	USAV2001/0081 - US - NP	

	Т	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	<del>-</del>
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), tille of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		SHI, et al., Molecular Cloning and Expression of Human Alveolar Macrophage Cathepsin S, an Elastinolytic Cysteins Proteass, J. Blol. Chem.; 1992; 267; pp.7258-7262.	!
		SINGH, et al., beta-lactams as Enzyme Inhibitors., IDrugs; 2000; 3(5); pp.512-517.	
		VILLADANGOS, et al., Cathepsin S Activity Regulates Antigen Presentation and Immunity, J. Clin. Invest; 1998; 101(10); pp.2351-2363.	
	,		
Examine	֡֡֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓	Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

